(Il Sole 24 Ore Radiocor) - Milano, 16 giu - US biopharmaceutical company Supernus Pharmaceuticals said it had agreed to buy Sage Therapeutics for 8.50 dollars a share in cash for an aggregate price of around 561 million dollars at closing.

The deal also includes a contingent value right collectively worth up to 3.50 dollars per share in cash, bringing the total value of the deal up to around 795 million dollars.

The CVR is payable upon achieving certain net sales and commercial milestones, Supernus said.

The transaction, which is expected to close in the third quarter of 2025, is expected to be significantly accretive to Supernus's earnings in 2026 with cost synergies of up to 200.

million dollars on an annual basis.

(RADIOCOR) 16-06-25 17:00:55 (0491) 5 NNNN